Skip to main content
. Author manuscript; available in PMC: 2012 Dec 4.
Published in final edited form as: Clin Cancer Res. 2011 Mar 3;17(7):1649–1657. doi: 10.1158/1078-0432.CCR-10-0567

Table 1.

Agents targeting AR in clinical development for metastatic CRPC

Mechanism of
action		 Drug Patient population Phase of
development		 Clinicaltrials.gov
registration
number
Rationally
designed specific
CYP 17 inhibitors		 Abiraterone
acetate		 chemotherapy treated Phase III – reported
at ESMO annual
meeting 2010 (19)		 NCT00638690
chemotherapy-naive Phase III NCT00887198
Orteronel (TAK-
700)		 chemotherapy treated Phase III NCT01193257
chemotherapy-naive Phase III NCT01193244
Novel AR
antagonists		 MDV-3100 chemotherapy treated Phase III NCT00974311
chemotherapy-naive Phase III NCT01212991
AZD3514 - Phase I/II NCT01162395
ARN-509 - Phase I/II NCT01171898
Dual CYP 17
inhibitors and AR
antagonist		 TOK-001 - Phase I/II NCT00959959